IDEXX Laboratories (IDXX) Fundamentals 2026 — P/E 40.1x, Revenue Analysis | SniperIQ
IDEXX Laboratories (IDXX) is a US-listed Healthcare company in Medical - Diagnostics & Research with a market capitalization of $43.3B, trading at $548.75 on the NASDAQ. This SniperIQ fundamentals page covers IDEXX Laboratories's valuation (P/E 40.1x, P/B 28.2x), profitability (net margin 24.6%), revenue ($4.3B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is IDEXX Laboratories's market cap?
IDEXX Laboratories (IDXX) has a market capitalization of approximately $43.3B, trading at $548.75 on the NASDAQ. Market cap moves with the live share price.
What is IDEXX Laboratories's P/E ratio?
IDEXX Laboratories's trailing twelve-month P/E ratio is 40.1x, with a price-to-book (P/B) of 28.2x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is IDEXX Laboratories?
IDEXX Laboratories runs a net profit margin of 24.6%, a gross margin of 62.1%, and an operating margin of 31.6%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does IDEXX Laboratories generate?
IDEXX Laboratories reported revenue of $4.3B for fiscal year 2025, with net income of
Does IDEXX Laboratories pay a dividend?
IDEXX Laboratories does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is IDEXX Laboratories financially healthy?
IDEXX Laboratories carries a debt-to-equity ratio of 0.71x and a current ratio of 1.12x, with a market beta of 1.55. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is IDEXX Laboratories a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For IDEXX Laboratories (IDXX) the key facts are: market cap $43.3B, P/E 40.1x, revenue $4.3B, 52-week range 518.55-769.98. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track IDEXX Laboratories's full fundamentals live
Get IDEXX Laboratories's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.